DAFTAR PUSTAKA

AA Pharma Inc. 2010. *Product Monograph Flunarizine Hydrochloride Capsules*. Vaughan Ontario.

Ahuja, S., and Dong, M. W. 2005. *Handbook of Pharmaceutical Analysis by HPLC*. Volume 6. Elsevier Inc. ISBN: 0-12-088547-6.

Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. 1995. A Theoretical Basis For A Biopharmaceutic Drug Classification: The Correlation Of In Vitro Drug Product Dissolution And In Vivo Bioavailability. *Pharmaceutical Research*, 12(3), 413–420.doi:10.1023/a:1016212804288.

Anand, O., Yu, L. X., Conner, D. P., and Davit, B. M. 2011. Dissolution Testing for Generic Drugs: An FDA Perspective. *The AAPS Journal*, Vol. 13, No. 3.

ASEAN Guideline on Stability Study of Drug Product (R1). Revision 25th ACCSQ-PPWG.

Badan Pengawas Obat dan Makanan RI. 2012. Pedoman Cara Pembuatan Obat yang Baik. Jakarta. ISBN 978-979-3707-65-5.

Balakrishnan, A., Rege, B. D., Amidon, G. L., & Polli, J. E. 2004. Surfactant-mediated dissolution: Contributions of solubility enhancement and relatively low micelle diffusivity. *Journal of Pharmaceutical Sciences*, 93(8), 2064–2075. doi:10.1002/jps.20118.

Bell, D. S., Muraco, C. E., and Flannery, C. 2018. Highlights from HPLC 2018 Symposium. *Research Gate*.

Benet, L. Z. 2013. The Role of BCS (Biopharmaceutics Classification System) and BDDCS (Biopharmaceutics Drug Disposition Classification System) in Drug Development. *Journal of Pharmaceutical Sciences*, 102(1), 34–42.doi:10.1002/jps.23359.

Brown, C. K. 2005. Dissolution Method Development: An Industry Perspective. In Dressman, J., and Krämer, J., Editor. *Pharmaceutical Dissolution Testing*. Taylor & Francis Group, LLC. ISBN-13: 978-0-8247-5467-9. Page. 357.

Busaranon, K., Suntornsuk, W., and Suntornsuk, L. 2005. Comparison of UV spectrophotometris method and high performance liquid chromatography for the analysis of flunarizine and its application for the dissolution test. *Journal of Pharmaceutical and Biomedical Analysis* 41 158–164.

Chan, C. C., Lam, H., Lee, Y. C., Zhang, X. M. 2004. *Analytical Method Validation and Instrument Performance Verification*. John Wiley & Sons, Inc. ISBN 0-471-25953-5.

Chen, L. R., Wesley, J. A., Bhattachar, S., Ruiz, B., Bahash, K., and Babu, S. R. 2003. Dissolution Behaviour of a Poorly Water Soluble Compound in the Presence of Tween 80. *Pharmaceutical Research, Vol. 20. No. 5*.

Chinese Pharmacopoeia Commission. 2011. *Pharmacopoeia of the People's Republic of China 2010*. Set of 3, English Edition, China Medical Science and Technology Press, Beijing.

Deepthi G, Balakrishnan M, Dr., Yadav K, Y. R., Mallika K, and Shekhar G, Muni. 2016. RP-Method Development for The Estimation of Flunarizine dihydrochloride in Tablet Dosage Form. *Indo American Journal of Pharmaceutical Research, Vol 6*(Issue 03), 32.

Deputi Bidang Pengawasan Produk Terapetik dan Napza Badan Pengawas Obat Dan Makanan. 2018. *Pedoman Sampling Produk Terapetik dan NAPZA Tahun 2018*. Badan POM RI.

Diebold, S. M. 2005. Physiological Parameters Relevant to Dissolution Testing: Hydrodynamic Considerations. In Dressman, J., and Krämer, J., Editor. *Pharmaceutical Dissolution Testing*. Taylor & Francis Group, LLC. ISBN-13: 978-0-8247-5467-9. Page. 127-183.

Dressman, J. B., Amidon, G. L., Reppas, C., & Shah, V. P. 1998. Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms. *Pharmaceutical Research*, 15(1), 11-22.

Dong, M. W. 2019. *HPLC AND UHPLC FOR PRACTICING SCIENTISTS*. Second Edition. John Wiley & Sons, Inc. USA. Page. 294.

Ermer, J., Miller, J. H. McB. 2005. *Method Validation in Pharmaceutical Analysis*. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim. ISBN: 3-527-31255-2.

Farmakope Indonesia Edisi V. 2014. Kementerian Kesehatan Republik Indonesia.

Fattah M, A., El Walily., El Gindy, A., and Wahbi, A. A. M. 1995. Spectrophotometric determination of Flunarizine duhydrochloride through the formation of charge-transfer complex with iodine. *Journal of Pharmaceutical & Biomedical Analysis*. Vol. 13 No. 1pp. 53-58. Elsevier Science Ltd.

Fotaki, N., Brown, W., Kochling, J., Chokshi, H., Miao, H., Tang, K., and Gray, V. 2013. Rationale for Selection of Dissolution Media: Three Case Studies. *Dissolution Technologies*. dx.doi.org/10.14227/DT200313P6.

Gray, V. A. 2005. Compendial Testing Equipment: Calibration, Qualification, and Sources of Error. In Dressman, J., and Krämer, J., Editor. *Pharmaceutical Dissolution Testing*. Taylor & Francis Group, LLC. ISBN-13: 978-0-8247-5467-9. Page. 39-65.

Harmita, Departemen Farmasi FMIPA UI. 2004. Petunjuk Pelaksanaan Validasi Metode dan Cara Perhitungannya. *Majalah Ilmu Kefarmasian*. Vol. I. No.3. hal. 117-135.

Hassan, B. A. R. 2012. HPLC Uses and Importance in the Pharmaceutical Analysis and Industrial Field. *Pharmaceutica Analytica Acta*.

Holmes, B., Brogden, R.N., Heel, R.C., Speight, T.M., and Avery, G.S. 1984. Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. *Drugs 27:6–44*. ©ADIS Press Limited.

Huber, L. 2003. Validation of Analytical Methods and Processes. In Nash, R. A., and Wachter, A. H., Editor. *Pharmaceutical Process Validation*. An International Third Edition. Marcel Dekker, Inc.

ICH Harmonised Tripartite Guideline. 2005. Validation of Analytical Procedures: Text and Methodology Q2(R1). Current Step 4 version. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.

ICH Topic Q 2 B. 1997. Validation of Analytical Procedures: Methodology. Step 4, Consensus Guideline. The European Agency for the Evaluation of Medicinal Products: Human Medicines Evaluation Units.

ICH Harmonised Guideline. 2018. Biopharmaceutics Classification System-Based Biowaivers. M9. ICH Consensus Guideline.

Kartinasari, W. F., Chufianty, H. and Indrayanto, G. 2003. HPLC Determination of Flunarizine Dihydrochloride in Tablets and Its Validation. *Journal of Liquid Chromatography & Related Technologies*, 26:7, 1059 – 1067. https://doi.org/10.1081/JLC-120020093

Khan, K. A. 1975. The Concept of Dissolution Efficiency. *Journal of Pharmacy and Pharmacology*, 27(1), 48–49. doi:10.1111/j.2042-7158.1975.tb09378.x.

Komite Akreditasi Nasional. 2004. SR 03: Jaminan Mutu Peralatan yang Digunakan oleh Laboratorium Pengujian Kimia dan Pengujian Biologi. DPLP 07 Rev. 0. Jakarta.

Krämer, J., Grady, L. T., and Gajendran, J. 2005. Historical Development of Dissolution Testing. In Dressman, J., and Krämer, J., Editor. *Pharmaceutical Dissolution Testing*. Taylor & Francis Group, LLC. ISBN-13: 978-0-8247-5467-9. Page. 14.

Li, M., Gao, Z., Wang, Z., Li, Z., & Wang, B. 2019. Measurement and correlation of solubility of flunarizine hydrochloride in ten pure and ethanol + n-propanol mixed solvents at temperatures within 293.15–333.15 K. *Journal of Molecular Liquids*, 112214. doi:10.1016/j.molliq.2019.112214.

Loftsson, T. 2015. Physicochemical Properties and Pharmacokinetics. *Essential Pharmacokinetics*, 85–104.doi:10.1016/b978-0-12-801411-0.00003-2.

Misiuk W. 2010. The role of assay methods in characterizing the quality of bulk pharmaceuticals. *J Pharm Bioall Sci;2:88-92.*

Moore, J.W. and Flanner, H.H. 1996. Mathematical Comparison of Curves with an Emphasis on in Vitro Dissolution Profiles. *Pharmaceutical Technology*, 20, 64-74.

Nagarajan, R. Polymer–Surfactant Interactions. 2001. In Detergents for the New Millennium, Proceeding of New Horizons Conference. *American Oil Chemists Society and Consumer Specialty Products Association*, Fort Myers, FL, Oct 14–17.

National Center for Biotechnology Information. 2020. *PubChem Database*. Flunarizine hydrochloride, CID=5282407, https://pubchem.ncbi.nlm.nih.gov/compound/Flunarizine-hydrochloride (accessed on May 29, 2020).

Niu, J., and Hu, R. 2017. Role of flunarizine hydrochloride in secondary brain injury following intracerebral hemorrhage in rats. *International Journal of Immunopathology and Pharmacology*.

Paithankar, H. V. 2013. HPLC METHOD VALIDATION FOR PHARMACEUTICALS: A REVIEW. *International Journal of Universal Pharmacy and Bio Sciences* 2(4): July-August.

Prashanth, K. N., Basavaiah, K., Raghu, M. S., Xavier, C. M., & Vinay, K. B. 2013. Determination of Flunarazine Dihydrchloride in Bulk Drug and Tablets by RP-UPLC: A Stability-Indicating Assay. *Proceedings of the National Academy of Sciences, India Section A: Physical Sciences*, 83(2), 79–88.doi:10.1007/s40010-013-0068-6.

Prashanth, K. N., Swamy, N., and Basavaiah, K. 2016. Investigation and Optimization of Titrimetric and Spectrophotometric Methods for the Assay of Flunarizine dihydrochloride Using *in situ* Bromine. *Acta Poloniae Pharmaceutica-Drug Research*, Vol. 73 No. 1 pp 35-45.

Shah, V. P. 2005. The Role of Dissolution Testing in the Regulation of Pharmaceuticals: The FDA Perspective. In Dressman, J., and Krämer, J., Editor. *Pharmaceutical Dissolution Testing*. Taylor & Francis Group, LLC. ISBN-13: 978-0-8247-5467-9. Page. 82.

Shah, V. P., & Amidon, G. L. 2014. A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of In Vitro Drug Product Dissolution and In Vivo Bioavailability, Pharm Res 12, 413–420, 1995—Backstory of BCS. *The AAPS Journal*, 16(5), 894–898. doi:10.1208/s12248-014-9620-9.

Showa Denko America. Inc., 25 Nopember 2018. *Lesson 1 : Introduction to HPLC*. https://shodexhplc.com/lessons/lesson-1-introduction-to-hplc/.

Skoog, D.A., Holler, F.J., and Crouch, S.R. 2006. *Principles of Instrumental Analysis*, 6e. Pacific Groves, CA: Brook Cole.

Stout, T. H., Dorsey, J. G. 2002. High-Performance Liquid Chromatography. In Ohannesian, Lena., and Streeter, Antony J., Editor. *Handbook of Pharmaceutical Analysis*. Marcel Dekker, Inc. New York. Page 103.

The Japanese Pharmacopoeia. Seventeenth Edition. 2016. English Version. Ministry of Health, Labour and Welfare. Japan.

The United States Pharmacopoeia 39–National Formulary 34. The United States Pharmacopoeial Convention, Inc.: Rockville, MD, 2016.

Upadhyay, S. K., and Ali, S. M. 2018. Molecular recognition of flunarizine dihydrochloride and β-cyclodextrin inclusion complex by NMR and computational approaches. *Chemistry Central Journal*.

U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER). December 2017. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System Guidance for Industry.

Van Nueten, J. M., and Vanhoutte, P. M. 1981. Calcium entry blockers and vascular smooth muscle heterogeneity. *Fed. Proc*., 40:2862-2865.

Van Nueten, J. M., and Janssen, P. A. J. 1973. Comparative study of the effects of flunarizine and cinnarizine on smooth muscle and cardiac tissues. *Arch. Int. Pharmacodyn. Ther*., 204:37-55.

Van Nueten, J. M., and Vanhoutte, P. M. 1984. Flunarizine. *New Drugs Annual: Cardiovaskular Drugs*. Vol. 2, edited by Alexander Scriabine. Raven Press New York.

Wang, Q., Ma, D., Higgins, J. P. 2006. Analytical Method Selection for Drug Product Dissolution Testing. *Dissolution Technologies*. dx.doi.org/10.14227/DT130306P6.